Received Jun 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
developed rashes on body around the injection site; developed rashes on body; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site rash in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, 2 weeks after receiving Shingles vaccine, the patient experienced injection site rash (Verbatim: developed rashes on body around the injection site) and generalized rash (Verbatim: developed rashes on body). The outcome of the injection site rash and generalized rash were not reported. It was unknown if the reporter considered the injection site rash and generalized rash to be related to Shingles vaccine. It was unknown if the company considered the injection site rash and generalized rash to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 29-MAY-2025 This case was reported by a patient via (Shingrix Chatbot) interactive digital media. The patient reported that after 2 weeks of getting second dose of Shingles vaccine had developed rashes on body and around the injection site